We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.04% | 4.85 | 4.70 | 5.00 | 4.85 | 4.80 | 4.80 | 300,969 | 12:33:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -11.55 | 25.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/5/2021 22:27 | supersonico 14 May '21 - 21:53 - 9364 > Let that sink in. A Bayer related crop protection RNS will land one day.. I have no doubt. Truly, without shame. | neutralpov | |
14/5/2021 21:53 | Those following the story will note that this recent flurry of news has not attracted the Bayer 7 like the Eden/Sipcam news did recently as mentioned in - post 9150 Instead it's been followed/liked by Corteva or Eastman employees widely like nothing that has been publicised before by Eden on Linked-in . Let that sink in. A Bayer related crop protection RNS will land one day.. I have no doubt. | supersonico | |
14/5/2021 14:12 | bjlk 14 May '21 - 09:20 - 9352 > This will never kick off. We got shafted by the Board and their agents. There, I fixed your typos for you. > I am still in Eejit. > no wonder the big boys are sitting on the side line!! They aren't sitting on the sidelines. They're nowhere, because they got big by not being stooopid. The smartest you'll find around here are the lying ramping filth on the payroll of "advisers", and shorters, et moi. | neutralpov | |
14/5/2021 13:30 | Optimistic but unlikely imo. | supersonico | |
14/5/2021 11:49 | Sounds reasonable Spadey, but I'm not clear as to why offering up a vague ballpark figure would on it's own be a detail that competitors could use to their advantage given the multiple details any commercial deal will involve. | supersonico | |
14/5/2021 11:42 | GMOs: Engineering the Nature out of Humanity, Webinar Replay with Dr. Zach Bush | supersonico | |
14/5/2021 11:17 | I've no idea..just trying to understand why.. when they know the commercial minimum value of this deal... why not make it public? | supersonico | |
14/5/2021 11:11 | Super Why would they possibly want a low share price? | fracman2 | |
14/5/2021 10:56 | Perhaps Eden want the share price low. Otherwise why not publish minimum contract value expectations? They no doubt would have worked all that out. | supersonico | |
14/5/2021 10:50 | Just for balance and any passive viewers out there, there are revenues immediately and for the coming years. Eden has regulatory approval in various countries for Mevalone and Cedroz with an estimated market and therefore potential annual revenue in due course of €174 million. Thus, it is down to Eastman, Sipcam, Sumi-Agro and a couple of others to go sell it directly to farmers. They will of course, buy stock from Eden to enable those sales purchases to follow through. Eden should make this abundantly clear in their communications so that the market fully understands the potential forward income ahead of them. Broker research papers will take a three-year forward view and clearly this has not been communicated sufficiently. If it had, Eden's share price would not have dropped. That Said, it is up to Eden to get the PI community to understand this fully too and this is not happening and has not been happening for several years. Unfortunately, it is a consistent negative. All of that said, Eden could turn this around in a heartbeat. It just takes a bit of time and consideration to deliver the story properly to the audience you are talking too. The future looks very bright for Eden, but the share price issue does need immediately addressing as it is in my opinion, very, very low in relation to where we are. The only way is up! | investingisatrickygame | |
14/5/2021 09:00 | Yes....no revenues | quazie12 | |
14/5/2021 08:58 | So no sales revenues for another couple of years ? | quazie12 | |
14/5/2021 07:38 | New Study: Agricultural Pesticides Cause Widespread Harm to Soil Health, Threaten Biodiversity Most Comprehensive Review Ever Conducted of Pesticide Impacts on Soil Finds Harm to Beneficial Invertebrates Like Beetles, Earthworms in 71% of Cases | supersonico | |
13/5/2021 17:43 | 2 risky 12 May '21 - 20:15 - 9347 > Some longterm investors here have produced and raised children to adulthood waiting for this to come good,quite a sobering thought. I expect some longterm investors will have topped themselves before this plays out. On the 0 to 10 subjective scale of M,A,C,S Alert backwards, this is a 9. But the supply of greedy, gullible idiots is almost limitless. Shrugs, well we have to eat... you idiots are on the menu. OK, I'll throw you fools a crumb: CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA CORTEVA Sing it to the tune of Battle Cry of the Republic (lol, popcorn) | neutralpov | |
12/5/2021 20:15 | Some longterm investors here have produced and raised children to adulthood waiting for this to come good,quite a sobering thought. | 2 risky | |
12/5/2021 18:52 | Tbh doesn't mention any volumes or metrics in the interview... emphasis on exclusive but no mention of payments for that exclusivity... I did pick up on the fact the market did not like the RNS .... anyone else? | timbo_slice | |
12/5/2021 17:41 | Correct, Where's the volumes in the RNS? | investingisatrickygame | |
12/5/2021 17:25 | Good positive video. Smith mentions that rhe Corteva deal includes minimum volumes. The RNS should have included this. | erinvale1 | |
12/5/2021 17:25 | Good positive video. Smith mentions that rhe Corteva deal includes minimum volumes. The RNS should have stated this. | erinvale1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions